

DAFTAR PUSTAKA

- Ahmed H. Abdelhafiz, Siobhan H.M. Brown, Aminu Bello, Meguid El Nahas; Chronic Kidney Disease in Older People: Physiology, Pathology or Both?. *Nephron Clinical Practice* 1 August 2010; 116 (1): c19–c24. <https://doi.org/10.1159/000314545>
- Alfano G, Perrone R, Fontana F, Ligabue G, Giovanella S, Ferrari A, Gregorini M, Cappelli G, Magistroni R, Donati G. Rethinking Chronic Kidney Disease in the Aging Population. *Life*. 2022; 12(11):1724
- Ammirati, A. L. (2020). Chronic kidney disease. In *Revista da Associacao Medica Brasileira* (Vol. 66, pp. 3–9). Associacao Medica Brasileira. <https://doi.org/10.1590/1806-9282.66.S1.3>
- Ameer, O. Z. (2022). Hypertension in chronic kidney disease: What lies behind the scene. In *Frontiers in Pharmacology* (Vol. 13). Frontiers Media S.A. <https://doi.org/10.3389/fphar.2022.949260>
- Arpino, V., Brock, M., & Gill, S. E. (2015). The role of TIMPs in regulation of extracellular matrix proteolysis. In *Matrix Biology* (Vols. 44–46, pp. 247–254). Elsevier B.V. <https://doi.org/10.1016/j.matbio.2015.03.005>
- Bikbov B, Perico N, and Remuzzi G., 2018. "Disparities in Chronic Kidney Disease Prevalence among Males and Females in 195 Countries: Analysis of the Global Burden of Disease 2016 Study". *Nephron*. 139 (4): 313– 318. Bülow RD, Boor P. Extracellular Matrix in Kidney Fibrosis: More Than Just a Scaffold. *J Histochem Cytochem*. 2019 Sep;67(9):643-661
- Cabral-Pacheco, G. A., Garza-Veloz, I., Rosa, C. C. D. La, Ramirez-Acuña, J. M., Perez-Romero, B. A., Guerrero-Rodriguez, J. F., Martinez-Avila, N., & Martinez-Fierro, M. L. (2020). The roles of matrix metalloproteinases and their inhibitors in human diseases. *International Journal of Molecular Sciences*, 21(24), 1–53. <https://doi.org/10.3390/ijms21249739>



- Chang, H. R., Yang, S. F., Li, M. L., Lin, C. C., Hsieh, Y. S., & Lian, J. Da. (2006). Relationships between circulating matrix metalloproteinase-2 and -9 and renal function in patients with chronic kidney disease. *Clinica Chimica Acta*, 366(1–2), 243–248. <https://doi.org/10.1016/j.cca.2005.10.007>
- Chen, T. K., Knicely, D. H., & Grams, M. E. (2019). Chronic Kidney Disease Diagnosis and Management: A Review. In *JAMA - Journal of the American Medical Association* (Vol. 322, Issue 13, pp. 1294–1304). American Medical Association. <https://doi.org/10.1001/jama.2019.14745>
- Cheng, Z., Limbu, M. H., Wang, Z., Liu, J., Liu, L., Zhang, X., Chen, P., & Liu, B. (2017). MMP-2 and 9 in chronic kidney disease. In *International Journal of Molecular Sciences* (Vol. 18, Issue 4). MDPI AG. <https://doi.org/10.3390/ijms18040776>
- Cockwell, P., & Fisher, L.-A. (2020). The global burden of chronic kidney disease. *The Lancet*, 395(10225), 698–708. [https://doi.org/10.1016/S0140-6736\(20\)30058-1](https://doi.org/10.1016/S0140-6736(20)30058-1)
- De Bhailis ÁM, Kalra PA. Hypertension and the kidneys. *Br J Hosp Med* (Lond). 2022 May 2;83(5):1-11. doi: 10.12968/hmed.2021.0440. Epub 2022 May 27
- Dewi, A. F., Harun, H., & Priyono, D. (2022). *Korelasi Antara Kadar Pentraxin-3 dan Matrix Metalloproteinase-9 Serum dengan Nilai Estimasi Laju Filtrasi Glomerulus pada Pasien Penyakit Ginjal Kronik*.
- Elinder, C.-G., Ahlberg, M., Allander, S. V., Alvestrand, A., & Bell, M. (2013). Methods to Estimate and Measure Renal Function (Glomerular Filtration Rate): A Systematic Review. *Swedish Council on Health Technology Assessment*.
- Fraser, S., & Blakeman, T. (2016). Chronic kidney disease: identification and management in primary care. *Pragmatic and Observational Research*, Volume 7, 21–32. <https://doi.org/10.2147/por.s97310>



- Gajjala, P. R., Sanati, M., & Jankowski, J. (2015). Cellular and molecular mechanisms of chronic kidney disease with diabetes mellitus and cardiovascular diseases as its comorbidities. *Frontiers in Immunology*, 6(JUN). <https://doi.org/10.3389/fimmu.2015.00340>
- Guillermo García, Arpana Iyengar, François Kaze, Ciara Kierans, Cesar Padilla-Altamira, Valerie A. Luyckx. Sex and gender differences in chronic kidney disease and access to care around the globe, *Seminars in Nephrology*, Volume 42, Issue 2, 2022, Pages 101-113, ISSN 0270-9295. <https://doi.org/10.1016/j.semnephrol.2022.04.001>
- Gorritz, J. L., & Martinez-Castelao, A. (2012). Proteinuria: Detection and role in native renal disease progression. In *Transplantation Reviews* (Vol. 26, Issue 1, pp. 3–13). W.B. Saunders. <https://doi.org/10.1016/j.trre.2011.10.002>
- Hill, N. R., Fatoba, S. T., Oke, J. L., Hirst, J. A., O'Callaghan, C. A., Lasserson, D. S., & Hobbs, F. D. R. (2016). Global prevalence of chronic kidney disease - A systematic review and meta-analysis. In *PLoS ONE* (Vol. 11, Issue 7). Public Library of Science. <https://doi.org/10.1371/journal.pone.0158765>
- Hruska, K. A., Seifert, M., & Sugatani, T. (2015). Pathophysiology of the chronic kidney disease - Mineral bone disorder. In *Current Opinion in Nephrology and Hypertension* (Vol. 24, Issue 4, pp. 303–309). Lippincott Williams and Wilkins. <https://doi.org/10.1097/MNH.0000000000000132>
- Hustrini, N. M., Susalit, E., & Rotmans, J. I. (2022). Prevalence and risk factors for chronic kidney disease in Indonesia: An analysis of the National Basic Health Survey 2018. *Journal of Global Health*, 12(04071). <https://doi.org/10.7189/jogh.12.04071>
- ah AG, Garovic VD. Understanding sex differences in progression and prognosis of chronic kidney disease. *Ann Transl Med*. 2020 Jul;8(14):897. doi: 10.21037/atm.2020.03.62



- Kalantar-Zadeh, K., Jafar, T. H., Nitsch, D., Neuen, B. L., & Perkovic, V. (2021). Chronic kidney disease. In *The Lancet* (Vol. 398, Issue 10302, pp. 786–802). Elsevier B.V. [https://doi.org/10.1016/S0140-6736\(21\)00519-5](https://doi.org/10.1016/S0140-6736(21)00519-5)
- Kovesdy, C. P. (2022). Epidemiology of chronic kidney disease: an update 2022. In *Kidney International Supplements* (Vol. 12, Issue 1, pp. 7–11). Elsevier B.V. <https://doi.org/10.1016/j.kisu.2021.11.003>
- MacRae, C., Mercer, S. W., Guthrie, B., & Henderson, D. (2021). Comorbidity in chronic kidney disease: A large cross-sectional study of prevalence in Scottish primary care. *British Journal of General Practice*, 71(704), E243–E249. <https://doi.org/10.3399/bjgp20X714125>
- Matovinović, M. S. (2009). Pathophysiology and Classification of Kidney Diseases. *EJIFCC*, 20(01). <http://www.ifcc.org>
- Miljkovic, M., Stefanovic, A., Bogavac-Stanojevic, N, et al. (2017). Association of Pentraxin-3, Galectin-3 and Matrix Metalloproteinase-9/TIMP-1 with Cardiovascular Risk in Renal Disease Patients. *Acta Clin Croat* 2017; 56:673-680.
- Moore, C. S., & Crocker, S. J. (2012). An alternate perspective on the roles of TIMPs and MMPs in pathology. In *American Journal of Pathology* (Vol. 180, Issue 1, pp. 12–16). Elsevier Inc. <https://doi.org/10.1016/j.ajpath.2011.09.008>
- Nangaku, M., Yamaguchi, J., & Tanaka, T. (2015). Recent advances in understanding of chronic kidney disease. In *F1000Research* (Vol. 4, pp. 1–9). Faculty of 1000 Ltd. <https://doi.org/10.12688/f1000research.6970.1>
- Narula, S., Tandon, C., & Tandon, S. (2017). Role of Matrix Metalloproteinases in Degenerative Kidney Disorders. *Current Medicinal Chemistry*, 25(15), 1805–1816. <https://doi.org/10.2174/0929867325666171205143441>
- obuiro, I., & Tuma, F. (2022). *Physiology, Renal*. StatPearls



- [Internet]. Treasure Island (FL): StatPearls Publishing.
- Portolés, J., Martín, L., Broseta, J. J., & Cases, A. (2021). Anemia in Chronic Kidney Disease: From Pathophysiology and Current Treatments, to Future Agents. In *Frontiers in Medicine* (Vol. 8). Frontiers Media S.A. <https://doi.org/10.3389/fmed.2021.642296>
- Qazi M, Sawaf H, Ismail J, Qazi H, Vachharajani T. (2022). Pathophysiology of Diabetic Kidney Disease. *EMJ Nephrol.* 2022;10[1]:102-113. DOI/10.33590/emjnephrol/22-00060
- Rayner, H. C. (2016). Kidney Anatomy and Physiology. In *Understanding Kidney Diseases*. Springer International Publishing. https://doi.org/10.1007/978-3-319-23458-8_1
- Riskesdas 2018., 2018. Depkes.go.id. 2018. Available from: <http://www.depkes.go.id/resources/download/info-terkini/hasil-riskesdas-2018.pdf>
- Roderfeld, M., Graf, J., Giese, B., Salguero-Palacios, R., Tschuschner, A., Müller-Newen, G., & Roeb, E. (2007). Latent MMP-9 is bound to TIMP-1 before secretion. *Biological Chemistry*, 388(11), 1227–1234. <https://doi.org/10.1515/BC.2007.123>
- Webster, A. C., Nagler, E. V., Morton, R. L., & Masson, P. (2017). Chronic Kidney Disease. In *The Lancet* (Vol. 389, Issue 10075, pp. 1238–1252). Lancet Publishing Group. [https://doi.org/10.1016/S0140-6736\(16\)32064-5](https://doi.org/10.1016/S0140-6736(16)32064-5)
- Wilson, S., Mone, P., Jankauskas, S. S., Gambardella, J., & Santulli, G. (2021). Chronic kidney disease: Definition, updated epidemiology, staging, and mechanisms of increased cardiovascular risk. In *Journal of Clinical Hypertension* (Vol. 23, Issue 4, pp. 831–834). Blackwell Publishing Inc. <https://doi.org/10.1111/jch.14186>
- zniak, J., Floege, J., Ostendorf, T., & Ludwig, A. (2021). Key metalloproteinase-mediated pathways in the kidney. In *Nature Reviews Nephrology* (Vol. 17, Issue 8, pp. 513–527). Nature



Research. <https://doi.org/10.1038/s41581-021-00415-5>

Yazgan, B., Avci, F., Memi, G., & Tastekin, E. (2021). Inflammatory response and matrix metalloproteinases in chronic kidney failure: Modulation by adropin and spexin. *Experimental Biology and Medicine*, 246(17), 1917–1927. <https://doi.org/10.1177/15353702211012417>

Zakiyanov, O., Kalousová, M., Zima, T., & Tesař, V. (2019). Matrix metalloproteinases in renal diseases: A critical appraisal. *Kidney and Blood Pressure Research*, 44(3), 298–330. <https://doi.org/10.1159/000499876>

Zhao, H. (2013). Matrix metalloproteinases contribute to kidney fibrosis in chronic kidney diseases. *World Journal of Nephrology*, 2(3), 84. <https://doi.org/10.5527/wjn.v2.i3.84>

